Show Me The Money: Xeris Rewrites Its Growth Story With A Blockbuster Revenue Ambition
Xeris Biopharma (XERS) aims for $1B+ revenue by 2030, up from $750M, driven by strong product performance. Q3 2026 revenue rose 43% YoY to $106.3M, with full-year 2026 guidance raised to $395-405M. Recorlev's growth and XP-8121 pipeline progress are key factors. Stock surged 153% to $17.28 by Nov. 2026.




